AVEG 003

A Phase I Multicenter, Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety ?and Immunogenicity of HIV-1 Recombinant ?Envelope Glycoprotein gp160

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) May 05, 1988
VaxSyn gp160 Vaccine (MicroGeneSys) Env gp160 B LAI
VaxSyn gp160 Vaccine (MicroGeneSys) Protein
USA 72